Aggressive treatment of early acute focal inflammatory activity to extend the window for BTK inhibition in multiple sclerosis
The development of novel therapy classes such as Bruton’s tyrosine kinase (BTK) inhibitors, which target disability progression independent of relapses and largely independent of new lesion formation, requires a reappraisal of strategies in the treatment of multiple sclerosis (MS). We argue that thi...
Сохранить в:
| Главные авторы: | , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
SAGE Publishing
2025-09-01
|
| Серии: | Therapeutic Advances in Neurological Disorders |
| Online-ссылка: | https://doi.org/10.1177/17562864251359002 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|